blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0979292

EP0979292 - GENE CONSTRUCT ENCODING A HETEROLOGOUS PRODRUG-ACTIVATING ENZYME AND A CELL TARGETING MOIETY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.09.2009
Database last updated on 02.09.2024
Most recent event   Tooltip30.09.2011Lapse of the patent in a contracting state
New state(s): CY		published on 02.11.2011  [2011/44]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2000/35]
Former [2000/20]For all designated states
AstraZeneca UK Limited
15 Stanhope Gate
London W1Y 6LN / GB
Former [2000/07]For all designated states
ZENECA LIMITED
15 Stanhope Gate
London W1Y 6LN / GB
Inventor(s)01 / EMERY, Stephen, Charles Zeneca Pharmaceuticals
Intell. Property Dept. Mereside, Alderley Park
Macclesfield Cheshire SK10 4TG / GB
02 / BLAKEY, David, Charles Zeneca Pharmaceuticals
Intell. Property Dept. Mereside, Alderley Park
Macclesfield Cheshire SK10 4TG / GB
[2000/07]
Representative(s)Giles, Allen Frank
AstraZeneca PLC
Global Intellectual Property
Mereside
Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
[N/P]
Former [2000/07]Giles, Allen Frank
AstraZeneca PLC Global Intellectual Property Mereside Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
Application number, filing date98919380.005.05.1998
[2000/07]
WO1998GB01294
Priority number, dateGB1997000942110.05.1997         Original published format: GB 9709421
[2000/07]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO9851787
Date:19.11.1998
Language:EN
[1998/46]
Type: A2 Application without search report 
No.:EP0979292
Date:16.02.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 19.11.1998 takes the place of the publication of the European patent application.
[2000/07]
Type: B1 Patent specification 
No.:EP0979292
Date:29.10.2008
Language:EN
[2008/44]
Search report(s)International search report - published on:EP01.04.1999
ClassificationIPC:C12N15/62, A61K48/00, // C07K16/28, C12N9/48
[2000/07]
CPC:
B82Y5/00 (EP,US); C12N15/00 (KR); A61K47/6899 (EP,US);
A61P35/00 (EP); A61P43/00 (EP); C07K16/3007 (EP,US);
C12N9/48 (EP,US); A61K38/00 (EP,US); A61K48/00 (EP,US);
C07K2319/00 (EP,US); C12N2799/022 (EP,US); Y10S977/804 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/07]
TitleGerman:GENKONSTRUKT DAS FÜR EIN HETEROLOGES "PRODRUG"-AKTIVIERENDES ENZYM UND FÜR EIN ZELLGERICHTES TEIL KODIERT[2000/07]
English:GENE CONSTRUCT ENCODING A HETEROLOGOUS PRODRUG-ACTIVATING ENZYME AND A CELL TARGETING MOIETY[2000/07]
French:CONSTRUCTION DE GENE CODANT POUR UNE ENZYME HETEROLOGUE CAPABLE D'ACTIVER UNE PRODROGUE ET UN GROUPEMENT VISANT UNE CELLULE[2008/20]
Former [2000/07]COMPOSES CHIMIQUES
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase10.12.1999National basic fee paid 
10.12.1999Designation fee(s) paid 
10.12.1999Examination fee paid 
Examination procedure02.11.1998Request for preliminary examination filed
International Preliminary Examining Authority: EP
10.12.1999Examination requested  [2000/07]
31.08.2005Despatch of a communication from the examining division (Time limit: M06)
07.03.2006Reply to a communication from the examining division
28.03.2007Despatch of a communication from the examining division (Time limit: M06)
04.09.2007Reply to a communication from the examining division
31.10.2007Despatch of a communication from the examining division (Time limit: M02)
24.12.2007Reply to a communication from the examining division
18.04.2008Communication of intention to grant the patent
17.07.2008Fee for grant paid
17.07.2008Fee for publishing/printing paid
Opposition(s)30.07.2009No opposition filed within time limit [2009/41]
Fees paidRenewal fee
15.05.2000Renewal fee patent year 03
10.05.2001Renewal fee patent year 04
06.05.2002Renewal fee patent year 05
07.05.2003Renewal fee patent year 06
05.05.2004Renewal fee patent year 07
13.05.2005Renewal fee patent year 08
27.03.2006Renewal fee patent year 09
07.05.2007Renewal fee patent year 10
18.03.2008Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.10.2008
BE29.10.2008
CY29.10.2008
DK29.10.2008
FI29.10.2008
NL29.10.2008
GR30.01.2009
PT30.03.2009
IE05.05.2009
LU05.05.2009
MC31.05.2009
[2011/44]
Former [2011/25]AT29.10.2008
BE29.10.2008
DK29.10.2008
FI29.10.2008
NL29.10.2008
GR30.01.2009
PT30.03.2009
IE05.05.2009
LU05.05.2009
MC31.05.2009
Former [2010/28]AT29.10.2008
BE29.10.2008
DK29.10.2008
FI29.10.2008
NL29.10.2008
PT30.03.2009
IE05.05.2009
MC31.05.2009
Former [2010/05]AT29.10.2008
BE29.10.2008
DK29.10.2008
FI29.10.2008
NL29.10.2008
PT30.03.2009
MC31.05.2009
Former [2009/32]AT29.10.2008
BE29.10.2008
FI29.10.2008
NL29.10.2008
PT30.03.2009
Former [2009/30]AT29.10.2008
FI29.10.2008
NL29.10.2008
PT30.03.2009
Cited inInternational search[X]EP0501215  (BEHRINGWERKE AG [DE]) [X] 1,2,14,15,17 * example - * * claim - *;
 [Y]WO9402450  (ZENECA LTD [GB], et al) [Y] 16,18 * claim - *;
 [XY]WO9515341  (CANCER RES CAMPAIGN TECH [GB], et al) [X] 1-5,7,8,14,15,17 * example 4 * * claim - * [Y] 6,9,16,18;
 [Y]WO9707769  (ZENECA LTD [GB], et al) [Y] 6,9 * example - * * claim - *;
 [X]  - R. BEGENT ET AL., "Single-chain Fv antibodies for targeting cancer therapy.", BIOCHEMICAL SOCIETY TRANSACTIONS, (199705), vol. 25, no. 2, pages 715 - 717, XP002092530 [X] 1-5,7,8,14,15,17 * the whole document *
 [X]  - K. BOSSLET ET AL., "Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation.", BRITISH JOURNAL OF CANCER, London, GB, (199202), vol. 65, no. 2, pages 234 - 238, XP002092531 [X] 1,2,14,15,17 * the whole document *
 [X]  - K. BOSSLET ET AL., "Tumor-selective prodrug activation by fusion protein-mediated catalysis.", CANCER RESEARCH, Baltimore, MD, USA, (19940415), vol. 54, no. 8, pages 2151 - 2159, XP002092532 [X] 1,2,14,15,17 * the whole document *
 [A]  - R. SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy.", ADVANCED DRUG DELIVERY REVIEWS, Amsterdam, The Netherlands, (1996), vol. 22, pages 269 - 288, XP000749297 [A] 1-18 * page 270, column R, line 17 - page 272, column R, line 33 * * page 280, column R, line 24 - line 32 *

DOI:   http://dx.doi.org/10.1016/S0169-409X(96)00450-4
 [A]  - H. SVENSSON ET AL., "Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates.", BIOCONJUGATE CHEMISTRY, Washington, DC, USA, (199405), vol. 5, no. 3, pages 262 - 267, XP000446101 [A] 7,8 * abstract *

DOI:   http://dx.doi.org/10.1021/bc00027a012
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.